Can Wegovy AKA Semaglutide Treat Alcoholism
youtu.be
Recent research has been exploring the potential of SEMAGLUTIDE, a GLP-1 receptor agonist, in treating alcohol use disorder (AUD). SEMAGLUTIDE affects the leptin and dopamine systems, which are linked to satiation and impulse control, respectively. It is theorized that SEMAGLUTIDE could reduce the motivation to consume alcohol by accelerating dopamine metabolism in the presence of alcohol. A Danish study involving 127 white male participants with an average age of 52 investigated the effects of EXENATIDE, a similar medication, on AUD. The study, which included cognitive behavioral therapy (CBT), found no significant difference between the treatment and placebo groups in reducing heavy drinking days and total alcohol intake. However, EXENATIDE did show a reduction in brain reactivity to alcohol cues and a lower AUD screening score six months post-treatment, suggesting it may decrease alcohol cravings. An exploratory analysis suggested that EXENATIDE might be more effective for obese patients, indicating a possible link between binge eating, obesity, and AUD. In a separate small American study with six patients, SEMAGLUTIDE showed promise in treating AUD, with all participants experiencing symptom improvement. However, the medication is not universally effective and has potential side effects. It is expensive, costing approximately $1500 per month, and there is a risk of weight gain or relapse after discontinuation, indicating that long-term use may be necessary. There is also a concern that patients might seek alternative substances if alcohol no longer provides the desired dopamine elevation. The effectiveness and mechanisms of SEMAGLUTIDE are still being investigated, with ongoing trials for various conditions. The early stage of research on GLP-1 agonists for AUD treatment calls for cautious optimism but not conclusive evidence for widespread use.
Recent research has been exploring the potential of SEMAGLUTIDE, a GLP-1 receptor agonist, in treati